Congratulations! Hzymes Awarded of "Hubei Sci-Tech Innovation 'New Species' Potential Unicorn"

According to the relevant requirements of the "Measures to Support the Cultivation and Development of Unicorn Enterprises" (Document No. 3 [2024] issued by the Office of the People's Government of Hubei Province) and the "Implementation Plan for the Hubei Province Sci-Tech Innovation 'New Species' Enterprise Cultivation Program" (Document No. 53 [2021] issued by the Hubei Provincial Science and Technology Department), the Hubei Provincial Science and Technology Department has identified the list of enterprises proposed to be included in the 2024 Hubei Province Sci-Tech Innovation "New Species" Enterprise database.

Hzymes Biotechnology Co., Ltd. (hereinafter referred to as "Hzymes") has been awarded the title of "Hubei Sci-Tech Innovation 'New Species' Potential Unicorn."

In recent years, potential unicorn enterprises, as the reserve forces for unicorn enterprises, have demonstrated significant development potential and growth prospects. They are typical representatives of technology-driven enterprises and have emerged as a new force in the entrepreneurial landscape of the new economy. They have become leaders in the new economy, creators of new dynamics, and pioneers of new tracks, attracting significant attention from various sectors of society. Since its establishment, Hzymes has been dedicated to the development and production of core raw materials in the biotechnology field.

Since its founding in 2015, the company has consistently focused on key areas such as in vitro diagnostic raw materials, biopharmaceuticals, the food industry, and environmental protection. The company has accumulated a total investment of nearly 1 billion yuan, and its current valuation is close to 5 billion yuan. The company has established marketing and R&D production centers in Shanghai, Wuhan, and Yichang, demonstrating a parallel advancement in multiple technology platforms and product areas. It has become a leading enterprise in the upstream raw material industry for biopharmaceuticals and in vitro diagnostics.

This honor not only recognizes the outstanding achievements of Wuhan Hzymes in the field of biopharmaceutical core raw materials but also affirms its significant future development potential. Furthermore, it will enhance the company's reputation and influence within the industry, attract more outstanding talents and partners, and drive greater breakthroughs in R&D and application in the field of biopharmaceutical core raw materials.

Looking ahead, Hzymes will continue to adhere to its innovation-driven development strategy, continuously increase R&D investment, and promote the innovation and application of core raw material technologies in biopharmaceuticals. The company will further expand its market presence, strengthen cooperation with domestic and international partners, jointly promote the application of biopharmaceutical raw material technologies in more fields, and make greater contributions to the sustainable development of human society.